Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Aceclidin
2. Aceclidine
3. Glaucadrine
4. Glaucocare
5. Glaucostat
6. Glaucotat
1. 6109-70-2
2. Quinuclidin-3-yl Acetate Hydrochloride
3. Aceclidine (hydrochloride)
4. Aceclidine Hcl
5. 3-acetoxyquinuclidine Hydrochloride
6. Aceclidine Hydochloride
7. 1-azabicyclo[2.2.2]oct-3-yl Acetate Hydrochloride
8. 1-azabicyclo[2.2.2]octan-3-yl Acetate;hydrochloride
9. 3b22o325q6
10. (+/-)-3-acetoxyquinuclidine Hydrochloride; 3-acetoxyquinuclidine Hydrochloride
11. Einecs 228-071-5
12. C 162 D
13. Unii-3b22o325q6
14. 1-azabicyclo(2.2.2)octan-3-ol, Acetate (ester), Hydrochloride
15. Aceclidine, Hydrochloride
16. 3-quinclidinol Dl-form Acetate Hydrochloride
17. 3-quinuclidinol, Acetate (ester), Hydrochloride
18. Schembl6237805
19. Chembl4303558
20. Dtxsid30976587
21. Ccg-39134
22. Mfcd00136230
23. Ab03765
24. Ccg-220635
25. Aceclidine Hydrochloride [mart.]
26. Aceclidine Hydrochloride [who-dd]
27. Db-053792
28. Ft-0621714
29. Sw220059-1
30. A833043
31. Sr-01000597817
32. 3-quinuclidinol Dl-form Acetate Hydrochloride
33. Sr-01000597817-1
34. Q27256986
35. 3-quinuclidinol Dl-form Acetate Hydrochloride [mi]
36. 1-azabicyclo[2.2.2]octan-3-yl Acetate--hydrogen Chloride (1/1)
| Molecular Weight | 205.68 g/mol |
|---|---|
| Molecular Formula | C9H16ClNO2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 2 |
| Exact Mass | 205.0869564 g/mol |
| Monoisotopic Mass | 205.0869564 g/mol |
| Topological Polar Surface Area | 29.5 Ų |
| Heavy Atom Count | 13 |
| Formal Charge | 0 |
| Complexity | 185 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Parasympathomimetics
Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. (See all compounds classified as Parasympathomimetics.)
Miotics
Agents causing contraction of the pupil of the eye. Some sources use the term miotics only for the parasympathomimetics but any drug used to induce miosis is included here. (See all compounds classified as Miotics.)
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35996
Submission : 2022-11-17
Status : Active
Type : II
NDC Package Code : 17337-0058
Start Marketing Date : 2014-08-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
NDC Package Code : 55486-1608
Start Marketing Date : 2024-09-19
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF



USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
NDC Package Code : 71604-0002
Start Marketing Date : 2022-10-24
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35996
Submission : 2022-11-17
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC Package Code : 17337-0058
Start Marketing Date : 2014-08-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 71604-0002
Start Marketing Date : 2022-10-24
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 55486-1608
Start Marketing Date : 2024-09-19
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : Established in 1984, Neuland Laboratories Limited is a publicly listed company headquartered in Hyderabad, India. The company provides solutions across the entire spectrum of the p...
About the Company : Conscientia Industrial is a pharmaceutical company, mainly developing, manufacturing, marketing APIs (Active Pharmaceutical Ingredients), intermediates, fine chemicals in China. We...

About the Company : J&H CHEM is one of China's leading providers of integrated fine chemical services including offering, research and development, Custom manufacturing business, as well as other Valu...

About the Company : NINGBO INNO PHARMCHEM CO.,LTD. develop, pilot and commercial produce organic chemicals, pharmaceutical intermediates and nutraceuticals. We also offer custom synthesis and manufact...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Vizz (aceclidine) is a cholinergic agonist, small molecule drug, which is indicated for the treatment of presbyopia in adults.
Lead Product(s): Aceclidine Hydrochloride,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Vizz
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 31, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aceclidine Hydrochloride,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
Details : Vizz (aceclidine) is a cholinergic agonist, small molecule drug, which is indicated for the treatment of presbyopia in adults.
Product Name : Vizz
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 31, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Under the terms of the licensing agreement, Théa will commercialize LNZ100 (aceclidine HCl) for the treatment of presbyopia in Canada.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Brand Name: Vizz
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Laboratoires Thea
Deal Size: Undisclosed Upfront Cash: $70.0 million
Deal Type: Licensing Agreement July 07, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Laboratoires Thea
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LENZ and Laboratoires Théa Announce Exclusive License Agreement for LNZ100 in Canada
Details : Under the terms of the licensing agreement, Théa will commercialize LNZ100 (aceclidine HCl) for the treatment of presbyopia in Canada.
Product Name : Vizz
Product Type : Miscellaneous
Upfront Cash : $70.0 million
July 07, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Under the licensing agreement, Lotus will holds the rights of LNZ100 (Aceclidine HCl) in Korea, which is being evaluated for the treatment of Presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Lotus Pharmaceutical
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 09, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Lotus Pharmaceutical
Deal Size : $125.0 million
Deal Type : Licensing Agreement
LENZ and Lotus Sign License Deal for LNZ100 in Korea and Southeast Asia
Details : Under the licensing agreement, Lotus will holds the rights of LNZ100 (Aceclidine HCl) in Korea, which is being evaluated for the treatment of Presbyopia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 09, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, being developed for the treatment of presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 27, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aceclidine Hydrochloride,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
CORXEL And LENZ Report Phase 3 Data for Presbyopia Drug LNZ100
Details : LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, being developed for the treatment of presbyopia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 27, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, being developed for the treatment of presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 21, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aceclidine Hydrochloride,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
LENZ Gets FDA Acceptance for LNZ100 NDA for Presbyopia Treatment
Details : LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, being developed for the treatment of presbyopia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 21, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, being developed for the treatment of presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 12, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aceclidine Hydrochloride,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
LENZ Submits NDA to FDA for LNZ100 to Treat Presbyopia
Details : LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, being developed for the treatment of presbyopia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 12, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The net proceeds will be used to fund the clinical advancement of LNZ100 (aceclidine & brimonidine tartrate), which is being evaluated in the late-stage clinical trial for the treatment of Presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Ridgeback Capital
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 15, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Ridgeback Capital
Deal Size : $30.0 million
Deal Type : Private Placement
LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital
Details : The net proceeds will be used to fund the clinical advancement of LNZ100 (aceclidine & brimonidine tartrate), which is being evaluated in the late-stage clinical trial for the treatment of Presbyopia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 15, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
LNZ101 is a fixed dose opthalmic solution of aceclidine (mAChRs agonist) & brimonidine (ADRA2 agonist), which is being evaluated for the treatment of presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 03, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
Details : LNZ101 is a fixed dose opthalmic solution of aceclidine (mAChRs agonist) & brimonidine (ADRA2 agonist), which is being evaluated for the treatment of presbyopia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 03, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The net proceeds will advance LENZ’s lead programs, LNZ100 and LNZ101, preservative-free, single-use, once-daily eye drops for treating presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Versant Ventures
Deal Size: $53.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 21, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Versant Ventures
Deal Size : $53.5 million
Deal Type : Private Placement
LENZ Completes Merger with Graphite Bio and Updates On Progress
Details : The net proceeds will advance LENZ’s lead programs, LNZ100 and LNZ101, preservative-free, single-use, once-daily eye drops for treating presbyopia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 21, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The collaboration will advance LENZ’s lead programs, LNZ100 and LNZ101, preservative-free eye drops containing aceclidine and aceclidine plus brimonidine for presbyopia treatment.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Graphite Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 21, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Graphite Bio
Deal Size : Undisclosed
Deal Type : Merger
LENZ Completes Merger with Graphite Bio and Provides Clinical and Corporate Update
Details : The collaboration will advance LENZ’s lead programs, LNZ100 and LNZ101, preservative-free eye drops containing aceclidine and aceclidine plus brimonidine for presbyopia treatment.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 21, 2024

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
39
PharmaCompass offers a list of Aceclidine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Aceclidine Hydrochloride manufacturer or Aceclidine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Aceclidine Hydrochloride manufacturer or Aceclidine Hydrochloride supplier.
PharmaCompass also assists you with knowing the Aceclidine Hydrochloride API Price utilized in the formulation of products. Aceclidine Hydrochloride API Price is not always fixed or binding as the Aceclidine Hydrochloride Price is obtained through a variety of data sources. The Aceclidine Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Aceclidine HCl manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Aceclidine HCl, including repackagers and relabelers. The FDA regulates Aceclidine HCl manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Aceclidine HCl API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Aceclidine HCl manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Aceclidine HCl supplier is an individual or a company that provides Aceclidine HCl active pharmaceutical ingredient (API) or Aceclidine HCl finished formulations upon request. The Aceclidine HCl suppliers may include Aceclidine HCl API manufacturers, exporters, distributors and traders.
click here to find a list of Aceclidine HCl suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Aceclidine HCl DMF (Drug Master File) is a document detailing the whole manufacturing process of Aceclidine HCl active pharmaceutical ingredient (API) in detail. Different forms of Aceclidine HCl DMFs exist exist since differing nations have different regulations, such as Aceclidine HCl USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Aceclidine HCl DMF submitted to regulatory agencies in the US is known as a USDMF. Aceclidine HCl USDMF includes data on Aceclidine HCl's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Aceclidine HCl USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Aceclidine HCl suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Aceclidine HCl as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Aceclidine HCl API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Aceclidine HCl as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Aceclidine HCl and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Aceclidine HCl NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Aceclidine HCl suppliers with NDC on PharmaCompass.
Aceclidine HCl Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Aceclidine HCl GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Aceclidine HCl GMP manufacturer or Aceclidine HCl GMP API supplier for your needs.
A Aceclidine HCl CoA (Certificate of Analysis) is a formal document that attests to Aceclidine HCl's compliance with Aceclidine HCl specifications and serves as a tool for batch-level quality control.
Aceclidine HCl CoA mostly includes findings from lab analyses of a specific batch. For each Aceclidine HCl CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Aceclidine HCl may be tested according to a variety of international standards, such as European Pharmacopoeia (Aceclidine HCl EP), Aceclidine HCl JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Aceclidine HCl USP).